Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Posch

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Cancer Immunology, Immunotherapy : CII|November 16, 2020
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Simon Fietz, Romina Zarbl, Dennis Niebel, et al.
Oncotarget|January 16, 2016
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsIgor Vujic, Martina Sanlorenzo, Rosaura Esteve-Puig, et al.
Oncotarget|October 4, 2014
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapiesIgor Vujic, Christian Posch, Martina Sanlorenzo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 3, 2025
Non-invasive characterization of melanoma depth at single-cell resolutionJuan Aguirre, Christine Gasteiger, Benedikt Hindelang, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanomaMartina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
The Journal of Investigative Dermatology|July 10, 2024
Loss of ERBB2 and ERBB3 Receptors Impacts Epidermal Differentiation in MiceTheresa Hommel, Paula F Meisel, Emanuela Camera, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|October 2, 2007
Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporineManfred Hecking, Alexander Kainz, Martin Schillinger, et al.
Cancer Biology & Therapy|March 22, 2014
Melanoma immunotherapyMartina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Ebiomedicine|October 21, 2023
The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitorsLaura Joachim, Sascha Göttert, Anna Sax, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 22, 2026
Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapyKristine E Mayer, Jessica C Hassel, Jannik Sambale, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Cancer Immunology, Immunotherapy : CII|November 16, 2020
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Simon Fietz, Romina Zarbl, Dennis Niebel, et al.
Oncotarget|January 16, 2016
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsIgor Vujic, Martina Sanlorenzo, Rosaura Esteve-Puig, et al.
Oncotarget|October 4, 2014
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapiesIgor Vujic, Christian Posch, Martina Sanlorenzo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 3, 2025
Non-invasive characterization of melanoma depth at single-cell resolutionJuan Aguirre, Christine Gasteiger, Benedikt Hindelang, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanomaMartina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
The Journal of Investigative Dermatology|July 10, 2024
Loss of ERBB2 and ERBB3 Receptors Impacts Epidermal Differentiation in MiceTheresa Hommel, Paula F Meisel, Emanuela Camera, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|October 2, 2007
Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporineManfred Hecking, Alexander Kainz, Martin Schillinger, et al.
Cancer Biology & Therapy|March 22, 2014
Melanoma immunotherapyMartina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Ebiomedicine|October 21, 2023
The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitorsLaura Joachim, Sascha Göttert, Anna Sax, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 22, 2026
Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapyKristine E Mayer, Jessica C Hassel, Jannik Sambale, et al.
Pageof 10